SCHEMBL10108670

SCHEMBL10108670

COc1ccccc1OCCN(CC(O)COc1cccc2[nH]c3ccccc3c12)C(C)(C)C

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 9/20 0.64
TLR4 O00206 7/20 0.64
DRD2 P14416 3/20 0.64
ADRB3 P13945 3/20 0.64
MAPT P10636 2/20 0.64
DNM1 Q05193 2/20 0.64
ADRB1 P08588 2/20 0.64
KDM4E B2RXH2 1/20 0.64
SLC22A2 O15244 1/20 0.64
SLC22A1 O15245 1/20 0.64
MLNR O43193 1/20 0.64
NR1I2 O75469 1/20 0.64
KCNK2 O95069 1/20 0.64
ABCB11 O95342 1/20 0.64
APP P05067 1/20 0.64
ABCB1 P08183 1/20 0.64
HTR1A P08908 1/20 0.64
ADRA2A P08913 1/20 0.64
ADORA3 P0DMS8 1/20 0.64
GAA P10253 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8277013 0.88 ADRB2 (0.68) ADRB2TLR4DRD2ADRB3MAPT
SCHEMBL4555826 0.88 ADRB2 (0.68) ADRB2TLR4DRD2ADRB3MAPT
SCHEMBL8199187 0.87 ADRB2 (0.67) ADRB2TLR4DRD2ADRB3MAPT
SCHEMBL7997039 0.86 ADRB2 (0.66) ADRB2TLR4DRD2ADRB3MAPT
SCHEMBL10123780 0.85 ADRB2 (0.65) ADRB2TLR4DRD2ADRB3MAPT
SCHEMBL13204418 0.85 ADRB2 (0.65) ADRB2TLR4DRD2ADRB3MAPT
SCHEMBL14582544 0.84 ADRB2 (0.63) ADRB2TLR4DRD2ADRB3MAPT
SCHEMBL13964556 0.84 ADRB2 (0.63) ADRB2TLR4DRD2ADRB3MAPT
SCHEMBL24831651 0.84 ADRB2 (0.58) ADRB2TLR4DRD2ADRB3MAPT
SCHEMBL5375723 0.83 ADRB2 (0.62) ADRB2TLR4DRD2ADRB3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101782-B2 Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory COLUCID PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-20080261950-A1 Compounds that inhibit cholinesterase COLUCID PHARMACEUTICALS, INC. (US) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261950-A1 Compounds that inhibit cholinesterase ACHE, BCHE, CHAT ADRB2 612/4885TLR4 4580/4885DRD2 1316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.